To define the upper limit of stone size amenable to CVAC treatment (Calyxo's CVAC® Aspiration System) in ureteroscopic renal stone removal.
Key Findings:
50 patients with 55 renal units included in the final analysis, indicating a significant sample size for the study.
Median stone size was 24.0 mm, suggesting a potential threshold for CVAC effectiveness.
48% had positive pre-operative urine cultures, which may impact surgical outcomes.
54% had multiple renal stones, highlighting the complexity of cases treated.
82% of patients were ASA Class 3 or 4, indicating a higher risk patient population.
Interpretation:
The study suggests that CVAC may be effective for stones larger than previously defined limits, indicating a need for further research to establish a definitive maximum size and its clinical implications.
Limitations:
Retrospective design may introduce bias in data collection and interpretation.
Limited follow-up duration may not capture long-term outcomes.
Single-center study may affect generalizability to broader populations.
Potential biases in patient selection could influence results.
Conclusion:
CVAC technology shows promise for larger stone removal, but further studies are required to determine the maximum stone size for successful treatment.
